Peptide Approaches to Long COVID Research
Post-Viral Immunity
10%
Estimated percentage of COVID-19 infections that result in long COVID symptoms persisting beyond 3 months, affecting an estimated 65 million people globally.
Davis et al., Nature Reviews Microbiology, 2023
Davis et al., Nature Reviews Microbiology, 2023
View as imageLong COVID affects an estimated 65 million people worldwide. The condition involves persistent symptoms (fatigue, cognitive dysfunction, exercise intolerance, autonomic dysfunction) lasting months to years after SARS-CoV-2 infection. A 2025 study in Nature Immunology confirmed what earlier work had suggested: long COVID involves sustained activation of proinflammatory pathways, upregulation of IL-6 and complement cascades, and expansion of exhausted T cell populations for more than 180 days after acute infection.[1] This is not "just" lingering fatigue. It is a measurable state of immune dysregulation with identifiable molecular signatures. Peptide-based approaches to long COVID target three of the condition's proposed mechanisms: immune exhaustion, viral persistence, and tissue damage. None are FDA-approved for this indication, and the clinical evidence ranges from preclinical plausibility to small observational studies. This article evaluates what the research actually shows. For broader context on post-viral immune recovery, see the pillar article on thymosin alpha-1.
Key Takeaways
- Long COVID involves T cell exhaustion (CD8+PD-1+TOX+ expansion), chronic inflammation (JAK-STAT, IL-6 upregulation), and possible viral persistence in tissue reservoirs
- Thymosin alpha-1 (Ta1) enhanced T cell maturation, improved interferon production, and reduced mortality in severe COVID-19 patients in a retrospective study of 76 critical cases in Wuhan (Thymalfasin reduced mortality from 30% to 11%)
- LL-37, the human cathelicidin, has demonstrated antiviral activity against SARS-CoV-2 in cell culture and modulates the inflammatory response through NF-kB pathway interactions
- BPC-157 has no published clinical data for long COVID; preclinical evidence is limited to general tissue repair and anti-inflammatory effects in animal models of gut and musculoskeletal injury
- No peptide therapy is FDA-approved for long COVID; all current use is investigational or off-label
- The RECOVER trial framework has identified candidate biomarker endpoints that could be used to evaluate peptide interventions in future clinical trials
The Immunology of Long COVID: What Peptides Would Need to Fix
T Cell Exhaustion
The most consistent immunological finding in long COVID is T cell dysfunction. Phetsouphanh and colleagues (2022) demonstrated that long COVID patients display increased frequencies of CD4+ T cells primed to migrate to inflamed tissues and exhausted SARS-CoV-2-specific CD8+ T cells, alongside elevated SARS-CoV-2 antibodies and a mis-coordination between T and B cell responses.[2]
A 2025 study identified expansion of CD8+PD-1+TOX+ T cells and CD4+ T cells with elevated CTLA-4 expression in long COVID cohorts up to 12 months post-infection. These populations showed reduced proliferative responses and diminished IL-2 production, classic markers of exhaustion that parallel the T cell dysfunction seen in chronic viral infections like HIV and hepatitis C.[3]
For peptide therapeutics, this means the target is not simply "boosting" the immune system. It is restoring coordinated immune function in a system that has become simultaneously overactive (chronic inflammation) and underperforming (exhausted effector responses). This dual dysfunction explains why simple immune stimulants are unlikely to help and why immunomodulatory peptides, which can both enhance depleted functions and dampen excessive inflammation, are theoretically more appropriate.
Viral Persistence
SARS-CoV-2 RNA and spike protein fragments have been detected in tissue biopsies (gut, brain, lymph nodes) months after acute infection in patients with long COVID symptoms. Gupta and colleagues (2025) reviewed the evidence for viral reservoirs and proposed that persistent viral antigens drive ongoing immune activation, which in turn maintains the exhausted T cell phenotype in a self-reinforcing loop.[4]
If viral persistence is a driver, then antimicrobial peptides with antiviral properties could theoretically address the root cause rather than just managing downstream inflammation. This is the rationale for LL-37 investigation, though translating this from cell culture antiviral activity to clearance of tissue-resident viral reservoirs in humans is a substantial leap.
Inflammatory Pathway Dysregulation
The RECOVER consortium's 2025 analysis confirmed that long COVID involves sustained upregulation of JAK-STAT signaling, IL-6, and complement pathways, along with metabolic reprogramming of immune cells.[1] This inflammatory signature may serve as both a diagnostic biomarker and a therapeutic target. Peptides that modulate NF-kB signaling, regulate cytokine production, or restore metabolic homeostasis in immune cells are all under investigation for this application.
Thymosin Alpha-1: The Most Studied Candidate
Thymosin alpha-1 (Ta1) is a 28-amino-acid peptide originally isolated from thymic tissue. It promotes T cell maturation, enhances dendritic cell function, increases interferon-alpha and interferon-gamma production, and modulates the balance between Th1 and Th2 immune responses. It is approved for hepatitis B treatment in over 30 countries and has decades of clinical safety data. For a comprehensive review of Ta1's mechanisms and evidence, see the pillar article on thymosin alpha-1 for post-viral immune recovery.
COVID-19 Evidence
During the acute pandemic, Ta1 was tested in severely ill COVID-19 patients in China. A retrospective study of 76 critical COVID-19 cases in Wuhan found that those receiving thymalfasin (the pharmaceutical form of Ta1) had significantly lower mortality (11.1% vs. 30.0%) and restored CD4+ and CD8+ T cell counts more rapidly than controls.[5] The treated group also showed reduced levels of inflammatory markers (IL-6, TNF-alpha, CRP).
The limitations are clear: this was retrospective, non-randomized, and conducted during acute critical illness, not long COVID. Whether Ta1 can reverse established T cell exhaustion months after infection, rather than preventing it during acute illness, is unknown. The biological rationale is plausible (Ta1 promotes thymic output of naive T cells, which could theoretically replenish exhausted populations), but the clinical question has not been tested in a controlled trial.
Relevance to Long COVID
Ta1's immunomodulatory profile matches several long COVID targets: it enhances depleted T cell function without broadly stimulating inflammation, it improves coordinated immune responses (the mis-coordination identified by Phetsouphanh et al. is precisely what Ta1 addresses in hepatitis B), and it has a favorable safety profile in immunocompromised populations. The gap between biological plausibility and clinical evidence remains wide, however. No published RCT has tested Ta1 specifically for long COVID.
For more on how immune reconstitution with peptide therapy works across different post-viral contexts, see the dedicated article.
LL-37: Antimicrobial Peptide with Antiviral Properties
LL-37 is the only human cathelicidin, a 37-amino-acid antimicrobial peptide produced by neutrophils, macrophages, and epithelial cells. It has broad-spectrum antimicrobial activity and immunomodulatory functions, including modulation of NF-kB signaling, chemokine induction, and wound healing promotion.
SARS-CoV-2 Activity
Wang and colleagues (2021) demonstrated that LL-37 has direct antiviral activity against SARS-CoV-2 in cell culture. The peptide appeared to interfere with viral entry by binding to the spike protein and competing with ACE2 receptor interaction. LL-37 also reduced viral-induced inflammatory cytokine production in infected cells.[6]
The antiviral mechanism is consistent with LL-37's known ability to disrupt enveloped virus membranes. SARS-CoV-2 is an enveloped virus, and LL-37's amphipathic structure allows it to insert into lipid bilayers and destabilize viral particles. However, the concentrations required for antiviral activity in cell culture (5-20 uM) are substantially higher than physiological LL-37 levels in most tissues (0.1-1 uM).
Long COVID Relevance
If viral persistence in tissue reservoirs drives long COVID, then an antimicrobial peptide that can reach these reservoirs and clear residual viral particles would address the root cause. The problem is delivery: LL-37 is rapidly degraded by proteases in plasma, has a half-life of minutes in circulation, and does not cross the blood-brain barrier (relevant for long COVID neurological symptoms). Intranasal or inhaled delivery could potentially address respiratory tract reservoirs but would not reach gut or lymph node compartments.
No clinical trial has tested LL-37 for long COVID. The evidence is limited to cell culture antiviral data and the peptide's known immunomodulatory properties. The theoretical rationale is sound but untested in humans for this indication.
BPC-157: The Evidence Gap
BPC-157 (Body Protection Compound-157) is a 15-amino-acid peptide derived from gastric juice that has shown tissue-protective and anti-inflammatory effects in numerous animal models. It has been cited in long COVID discussions within the functional medicine and peptide therapy communities.
The honest assessment: there is no published clinical data, no published preclinical data, and no registered clinical trial testing BPC-157 for long COVID or any post-viral syndrome. The peptide's proposed mechanisms (angiogenesis promotion, gut barrier repair, anti-inflammatory signaling) are theoretically relevant to some long COVID symptoms, particularly GI involvement and tissue repair. But theory without data is not evidence. BPC-157 remains an experimental compound that has not completed any Phase 2 or Phase 3 clinical trial for any indication as of 2026.[7]
Other Peptide Candidates Under Investigation
KPV is a tripeptide (Lys-Pro-Val) derived from alpha-melanocyte-stimulating hormone that inhibits NF-kB activation. Its anti-inflammatory mechanism is relevant to the chronic inflammation signature of long COVID, but published evidence is limited to colitis models in animals.
MOTS-c is a mitochondrial-derived peptide that activates AMPK and improves cellular metabolism. Long COVID involves mitochondrial dysfunction and metabolic reprogramming in immune cells, making MOTS-c a biologically plausible candidate. However, no clinical data exists for this application.
Selank is a synthetic peptide anxiolytic that modulates GABA and serotonin signaling. It has been proposed for long COVID neuropsychiatric symptoms (brain fog, anxiety, depression) based on its nootropic and anxiolytic effects in Russian clinical studies. The evidence base is thin by FDA standards, and the neuropsychiatric mechanism of long COVID may involve neuroinflammation rather than the neurotransmitter imbalance that Selank addresses.
The Broader Context: Peptide Immunomodulation Beyond COVID
Long COVID has drawn attention to a larger question: can peptide-based immunomodulators restore function in dysregulated immune systems? The same T cell exhaustion phenotype seen in long COVID occurs in chronic hepatitis B (where thymosin alpha-1 is an approved treatment), chronic hepatitis C, HIV, and cancer. Lessons from these fields inform the long COVID peptide discussion.
The antimicrobial peptide field also offers relevant insights. LL-37's role in long COVID research sits within a broader body of work on how defensins and cathelicidins defend against respiratory pathogens. The innate immune system's first-line peptide defenses may determine initial viral load and subsequent likelihood of developing persistent infection, meaning that endogenous antimicrobial peptide levels could be both a risk factor for and a therapeutic target in long COVID.
The gut is increasingly recognized as a key site of long COVID pathology. Viral persistence in intestinal tissue, disrupted gut barrier function, and altered microbiome composition are all documented in long COVID patients. Peptides with gut-protective properties, including BPC-157 (in animal models) and KPV (through NF-kB modulation in colonic epithelium), are being investigated for this reason, though clinical evidence is absent. The relationship between gut peptide signaling and immune function connects to the broader understanding of how your gut bacteria produce antimicrobial peptides that shape systemic immune responses.
The fatigue and exercise intolerance that characterize long COVID may also involve mitochondrial dysfunction, which links to research on MOTS-c and cellular energy metabolism. Whether exogenous mitochondrial-derived peptides can compensate for the metabolic dysfunction observed in long COVID immune cells is an untested but biologically coherent hypothesis.
What Would a Rigorous Long COVID Peptide Trial Look Like?
The RECOVER consortium has established infrastructure for long COVID clinical trials, including validated outcome measures and candidate biomarker endpoints. A well-designed peptide trial would need:
- Patient stratification based on immunological phenotype (exhausted T cells, elevated inflammatory markers, evidence of viral persistence) rather than symptom-based inclusion alone
- Biomarker-driven endpoints: CD8+ T cell exhaustion markers (PD-1, TOX), inflammatory cytokines (IL-6, TNF-alpha), and viral persistence markers (spike protein detection) alongside patient-reported outcomes
- Adequate sample size: the RECOVER framework estimates that 200-400 participants per arm are needed for adequate power given the heterogeneity of long COVID
- Active comparator: ideally compared to emerging standard-of-care interventions rather than placebo alone
Until such trials are conducted, peptide approaches to long COVID remain in the hypothesis-generating phase. The biological rationale for several candidates is sound, but the clinical evidence does not yet support therapeutic use.
The Bottom Line
Long COVID involves measurable immune dysregulation: T cell exhaustion, chronic inflammation, and possible viral persistence. Several peptide-based approaches have biological rationale for addressing these mechanisms. Thymosin alpha-1 has the strongest supporting evidence, including retrospective data from acute COVID-19 showing reduced mortality and restored T cell counts, though no long COVID-specific RCT exists. LL-37 demonstrates antiviral activity against SARS-CoV-2 in cell culture but faces major delivery challenges. BPC-157 has no published evidence for any post-viral indication. The gap between biological plausibility and clinical proof remains the defining feature of this field. Well-designed trials using immunological biomarkers and the RECOVER framework infrastructure are needed before peptide therapies can be recommended for long COVID.